文献速递脑血管病外科神经重症

氨甲环酸对自发性脑出血神经外科干预的影响:来自氨甲环酸治疗脑出血-2随机对照试验中121例手术治疗参与者的数据

The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial.
PubMed 文献 · Neurosurgery · 2024-05-24

本研究基于TICH-2随机对照试验数据,分析121例接受神经外科手术的自发性脑出血患者。结果显示,氨甲环酸组与安慰剂组手术率相似(4.9% vs 5.5%,OR 0.893,95%CI 0.619-1.289,P=0.545),氨甲环酸未改善手术患者结局(OR 0.79,95%CI 0.30-2.09,P=0.64),也未减少术后血肿体积(平均差-8.97,95%CI -23.77至5.82,P=0.45)。

要点

  • 氨甲环酸组手术率4.9%(57/1153)与安慰剂组5.5%(64/1163)相似,OR 0.893(95%CI 0.619-1.289,P=0.545)。
  • 手术治疗患者中,氨甲环酸组与安慰剂组功能结局无显著差异(OR 0.79,95%CI 0.30-2.09,P=0.64)。
  • 氨甲环酸未降低术后血肿体积(平均差-8.97,95%CI -23.77至5.82,P=0.45)。

核心结论

  • 氨甲环酸与减少神经外科干预、降低血肿体积或改善术后结局无关。

研究设计与样本

  • TICH-2随机对照试验的事后分析,纳入121例接受神经外科手术的自发性脑出血参与者,比较氨甲环酸组与安慰剂组。

主要发现

  • 2325例参与者中5.2%(121/2325)接受神经外科手术,包括开颅术(57%)、血肿引流(33%)和脑室外引流(21%)。
  • 接受手术的患者中,氨甲环酸组为4.9%(57/1153),安慰剂组为5.5%(64/1163),OR 0.893(95%CI 0.619-1.289,P=0.545)。
  • 手术治疗参与者中,氨甲环酸组与安慰剂组结局无显著差异(OR 0.79,95%CI 0.30-2.09,P=0.64)。
  • 接受血肿清除(引流或开颅)的参与者中,氨甲环酸组与安慰剂组结局无显著差异(OR 1.19,95%CI 0.51-2.78,P=0.69)。
  • 术后血肿体积未因氨甲环酸而减少(平均差-8.97,95%CI -23.77至5.82,P=0.45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: An important proportion of patients with spontaneous intracerebral hemorrhage (ICH) undergo neurosurgical intervention to reduce mass effect from large hematomas and control the complications of bleeding, including hematoma expansion and hydrocephalus. The Tranexamic acid (TXA) for hyperacute primary IntraCerebral Hemorrhage (TICH-2) trial demonstrated that tranexamic acid (TXA) reduces the risk of hematoma expansion. We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set. METHODS: Participants enrolled in TICH-2 were randomized to placebo or TXA. Participants randomized to either TXA or placebo were analyzed for whether they received neurosurgery within 7 days and their characteristics, outcomes, hematoma volumes (HVs) were compared. Characteristics and outcomes of participants who received surgery were also compared with those who did not. RESULTS: Neurosurgery was performed in 5.2% of participants (121/2325), including craniotomy (57%), hematoma drainage (33%), and external ventricular drainage (21%). The number of patients receiving surgery who received TXA vs placebo were similar at 4.9% (57/1153) and 5.5% (64/1163), respectively (odds ratio [OR] 0.893; 95% CI 0.619-1.289; P -value = .545). TXA did not improve outcome compared with placebo in either surgically treated participants (OR 0.79; 95% CI 0.30-2.09; P = .64) or those undergoing hematoma evacuation by drainage or craniotomy (OR 1.19 95% 0.51-2.78; P -value = .69). Postoperative HV was not reduced by TXA (mean difference -8.97 95% CI -23.77, 5.82; P -value = .45). CONCLUSION: TXA was not associated with less neurosurgical intervention, reduced HV, or improved outcomes after surgery.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Hollingworth M, Woodhouse LJ, Law ZK, et al. The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial. Neurosurgery. 2024. PMID: 38785451. doi:10.1227/neu.0000000000002961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。